Abcam

Abcam Plc is a global life science company, which distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays, and other kits. The company was founded by David Douglas Cleevely, Anthony Kouzarides, and Jonathan Simon Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.

Danaher

Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports.

Danaher acquires biotech supplier Abcam for $5.7B

Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.

Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln

The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.

Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.

Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday.

Abcam agrees to be acquired by Danaher in $5.7B deal

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction').

Danaher to acquire Abcam for $24.00 per Share

WASHINGTON , Aug. 28, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion including assumed indebtedness and net of acquired cash. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research, and diagnostics.

Danaher to Acquire Abcam

Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday.

Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources

Here is how Abcam PLC Sponsored ADR (ABCM) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Abcam (ABCM) This Year?

CAMBRIDGE, England and WALTHAM, Mass. , July 12, 2023 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today held an Extraordinary General Meeting of its shareholders (the "EGM") that was convened following a requisition notice from Dr. Jonathan Milner dated May 30, 2023 (the "Requisition Notice").

Abcam plc: All Resolutions Withdrawn at Abcam's EGM

CAMBRIDGE, England , July 5, 2023 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following preliminary trading update for the half ending 30 June 2023.     Preliminary results Period Estimated Reported Revenue Estimated Adjusted Operating Profit % H1 2023 >£203 million >26%   First half 2023 estimated revenues grew approximately 10% on a reported basis or 5.5% on a constant exchange rate basis as compared to 20% growth on a constant exchange rate basis in the comparable prior period.

ABCAM PLC: Trading Update

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today confirmed that it has received a letter of undertaking from Dr. Jonathan Milner withdrawing his notice dated May 30, 2023 (the “Requisition Notice”) which required the Company to call an Extraordinary General Meeting of its shareholders (the “EGM”) to consider certain resolutions proposed by him (the “Resolutions”). In.

Abcam Confirms Dr. Jonathan Milner has Withdrawn EGM Requisition Notice and Related Resolutions

NEW YORK--(BUSINESS WIRE)--Starboard Value LP (together with its affiliates, “Starboard” or “we”), a significant shareholder of Abcam plc (“Abcam” or the “Company”) (Nasdaq: ABCM), today issued the following statement: “We believe there is significant value in Abcam and are supportive of the Company running a full sale process to maximize value for all shareholders. We are supportive of Dr. Milner's stated plan to temporarily suspend his solicitation to allow Abcam's Board of Directors to run a.

Starboard Issues Statement Regarding the Opportunity to Maximize Value at Abcam

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following updates. Although the Company acknowledges that these financial updates are being provided outside our normal reporting cycles, the Board and management team believe that it is in the best interests of shareholders to provide this updated disclosure given the extraordinary circumstances that the C.

Abcam plc: FY2024 Guidance

Abcam specializes in products, such as assays or reagents, used in biologic drug discovery. The company saw revenue grow but reported a loss in 2022.

Why Shares of Abcam Are Jumping Friday

CAMBRIDGE, England and WALTHAM, Mass. , June 23, 2023 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces that, having listened to and extensively engaged with shareholders, the Board of Directors has unanimously decided to initiate a process to explore strategic alternatives for the Company.

Abcam Announces Review of Strategic Alternatives

Does Abcam PLC Sponsored ADR (ABCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Abcam PLC Sponsored ADR (ABCM) is a Great Choice

Allegiant Travel Company

Maxeon Solar Technologies

As brokers have a deeper insight into stocks, one must follow rating upgrades for solid returns. We choose Abcam (ABCM), Maxeon Solar (MAXN) and Allegiant Travel (ALGT) as these witness rating upgrades.

3 Stocks With Upgraded Broker Ratings for Robust Returns

Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year.

Is Abcam (ABCM) Outperforming Other Medical Stocks This Year?

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc ("Abcam,” "Company,” "Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today filed an investor presentation with the U.S. Securities and Exchange Commission (“SEC”) in connection with the Extraordinary General Meeting of the Company (the “EGM”) to be held on July 12, 2023 at 2:00pm (BST) || 9:00am (EDT). The full presentation and other materials related to the EGM are available at https://corpor.

Abcam Highlights Successful Execution of Strategic Priorities to Drive Shareholder Value

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today filed and mailed a shareholder circular (the “Shareholder Circular”) calling an Extraordinary General Meeting (the “EGM”) to be held on July 12, 2023 at 2:00pm (BST) || 9:00am (EDT). The Board of Directors of the Company (the “Board”) was required to call the EGM following the receipt on May 30, 2023 of a notice from Dr.

Abcam plc files and mails Shareholder Circular calling an Extraordinary General Meeting

Abcam operates in some highly attractive end markets, but its operational execution is not what it should be, according to its funder and former director. Dr. Jonathan Milner has called for the removal of three board members and his appointment as executive chairman.

Why Shares in Abcam Surged This Week

Abcam plc's outlook remains unchanged after a mixed FY'22, with improvements needed in fundamental, sentiment, and valuation factors to attract buyers. Despite a strong FY'22, ABCM's poor returns on capital, economic losses and flat growth outlook hinder its investment potential. The company needs to enhance performance across key metrics to create value for shareholders and warrant a buy rating.

Abcam: Nosebleed Valuations, Flat Growth Profile Justify Hold Rating

CAMBRIDGE, England and WALTHAM, Mass. , May 30, 2023 /PRNewswire/ --  Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, notes that it has received a notice from Dr. Jonathan Milner seeking to require the Board of Directors to convene an Extraordinary General Meeting (the "EGM").

ABCAM PLC: Statement on calling an Extraordinary General Meeting

Jonathan Milner c alls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control

Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control

The mean of analysts' price targets for Abcam PLC Sponsored ADR (ABCM) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for Abcam Stock (ABCM)